SPRY
Ars Pharmaceuticals Stock Analysis
AI Rating
- Quality3/10
- Growth↓ 1/10
- Momentum↓ 3/10
SPRY Growth
- Revenue Y/Y↑ 5459.66%
- EPS Y/Y↓ -60.78%
- FCF Y/Y↓ -86.87%
SPRY Profitability
- Gross margin ↑ 89.40%
- EPS margin↓ -56.10%
- ROIC↓ -23.50%
SPRY Risk
- Debt / Equity↓ 1.2
- Debt / FCF↓ 1.3
- Interest coverage↓ NA
Ars Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Good risk rating.